Do you want to volunteer for Clinical Trials? Register now

Advertise Your Study

To advertise your Clinical Trial with MedTrials.co.uk, please fill in the form below. If you have an online advertisement already, we can advertise the study and provide links to your own online registration form. Information provided below will form the basis of your study online brief. Alternatively, you can contact us.

Volunteers that apply directly to your study will not join the MedTrials "registered volunteers" list that is mailed out on monthly basis (unless they choose to do so).

Clinical Investigator Services

CRO’s, Pharmaceutical companies and Clinical Investigators have access to a number of services:

Recruit Volunteers for your Medical Trial

MedTrials.co.uk offers access to our comprehensive database of candidates interested in taking part in Phase 1 Medical Trials.

Advertise your Medical Trial

MedTrials.co.uk has been developed to ensure we have maximum exposure on the Internet. This creates a perfect platform for you to advertise your Clinical Trials to reach as many volunteers as possible.

Through intelligent website optimisation and effective advertising campaigns, we ensure that MedTrials.co.uk remains at the top of search engine listings on the Internet.

As a Clinical Research Organisation or Clinical Investigator you can either advertise your specific trail with us or you can search a ready made list of candidates that are interested in hearing more about studies that may be taking place in the future.

CRO’s, Pharmaceutical Companies and Clinical Investigators can advertise their medical trials on our searchable advertising board.

Access to Medtrials.co.uk volunteer database

MedTrials.co.uk is an extensive current database of candidates interested in taking part in Phase I Medical Trials. Data collected includes contact details including address, phone and email together with data about the volunteer’s medical history.

Why should I advertise my Clinical Trial with MedTrials?

Difficulty recruiting? Additional resource to minimise delay in recruitment etc.

Relevant Applicants Instantly - MedTrials.co.uk has invested a large amount of advertising spend to ensure that we are consistently near the top of search engine listings. By using targeted, selective advertising methods, we ensure that only interested, relevant volunteers are attracted to our website. Massive online traffic to our website means that by advertising with MedTrials, you can access a large population of volunteers very quickly. You can also search the database for suitable candidates.

Simple Pricing, cost-effective - You will only be charged once for the price of each advert regardless of how many applicants you receive.

News

Accenture joins Partnership on AI

Accenture has joined the Partnership on AI, an alliance of businesses, researchers, academics and policy makers that work to advance the understanding of artificial intelligence (AI) technology and develop best practices on the challenges and opportunities within the field. Accenture joins other prominent industry leaders who share its commitment to advancing the field of AI so […]

more >

AMRA, BioTelemetry partner on NASH/NAFLD clinical trials

AMRA, the international leader in body composition analysis, and BioTelemetry Research (BTR), a global imaging and cardiac core lab, announced the formation of an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials. This first-to-market partnership will advance imaging science and benefit clinical trial sponsors in several musculoskeletal and metabolic […]

more >

FDA approves CAR-T cell therapy for large B-cell lymphoma

The FDA approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the […]

more >

Phase III Lusutrombopag study shows positive efficacy

Shionogi & Co. announced it will present positive efficacy and safety results from a global phase III study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C. L-PLUS 2 […]

more >

Institut Curie, Pierre Fabre Partner on immuno-oncology

Institut Curie and the IRPF (Institut de Recherche Pierre Fabre) will collaborate on new therapeutic strategies to advance cancer treatment for patients. The objective of this novel partnership is to dissect the biology of novel therapeutically tractable targets and evaluate the impact of innovative pharmacological approaches leveraging the Institut Curie’s biological models. “We will work […]

more >

Type 2 diabetes: Blood sugar pill shows promise

In a 26-week phase II clinical trial for type 2 diabetes patients, glycemic control using semaglutide in pill form was better than using a placebo. Powered by WPeMatico

more >